<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b4a5d72b-3487-45b0-a45d-65c50117832f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use Meloxicam Tablets USP safely and effectively. See full prescribing information for Meloxicam Tablets USP.<br/>
      <br/>Meloxicam Tablets USP, for oral use<br/>Initial U.S. Approval: 2000</title>
   <effectiveTime value="20181228"/>
   <setId root="dfaac71c-dcc5-4b57-bf3b-616fccab96de"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="967795266" root="1.3.6.1.4.1.519.1"/>
            <name>Exelan Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="080938961" root="1.3.6.1.4.1.519.1"/>
                        <name>Ascent Pharmaceuticals Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76282-152" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76282-152" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76282-153" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76282-153" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="aa39b077-048b-4852-8ebd-9f8ff1cc228c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20181231"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76282-152" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Meloxicam</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Meloxicam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="7.5" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MELOXICAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MELOXICAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-152-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-152-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-152-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-152-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077927" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150414"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>Light Yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>Flat, Beveled Edge</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="7"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">T;152</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76282-153" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Meloxicam</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Meloxicam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="15" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MELOXICAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MELOXICAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-153-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-153-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-153-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="76282-153-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150414"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077927" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150414"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>Light Yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE">
                              <originalText>Biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="11"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">T;153</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="783cef24-7e98-4283-9c61-a22a1761a138"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning Section"/>
               <title>WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS</title>
               <text>
                  <paragraph styleCode="Default"/>
                  <paragraph styleCode="Default">
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph styleCode="Default">
                     <content styleCode="bold">
                        <content styleCode="underline">Cardiovascular Thrombotic Events</content>
                     </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [<content styleCode="italics">see Warnings and Precautions (5.1)</content>]. </content>
                     </item>
                     <item>
                        <content styleCode="bold">Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [<content styleCode="italics">see Contraindications (4) and Warnings and Precautions (5.1)</content>].</content>
                     </item>
                  </list>
                  <paragraph/>
                  <paragraph styleCode="Default">
                     <content styleCode="bold">
                        <content styleCode="underline">Gastrointestinal Bleeding, Ulceration, and Perforation</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [<content styleCode="italics">see Warnings and Precautions (5.2)</content>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20171225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning</content>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (5.1) </content>
                           </item>
                           <item>
                              <content styleCode="bold">Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1) </content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (5.2)</content>
                        </paragraph>
                        <content styleCode="bold"/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L7a4133d4-20a0-4794-9fb4-89c27c33bf9d">
               <id root="3d3be8a5-4ead-4d02-a116-a3e510355049"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20171225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph styleCode="Default">Boxed Warning                                                                   5/2016                                                                              </paragraph>
                        <paragraph styleCode="Default">Indications and Usage, Juvenile Rheumatoid Arthritis (JRA) </paragraph>
                        <paragraph styleCode="Default">
                           <content>Pauciarticular and Polyarticular Course (1.3)                           6/2016                                 </content>
                        </paragraph>
                        <paragraph styleCode="Default">Dosage and Administration, General Dosing Instructions (2.1)  <content>6/2016</content>
                        </paragraph>
                        <paragraph styleCode="Default">Dosage and Administration, Juvenile Rheumatoid Arthritis (JRA) </paragraph>
                        <paragraph styleCode="Default">Pauciarticular and Polyarticular Course (2.4)                            6/2016                                 </paragraph>
                        <paragraph styleCode="Default">Warnings and Precautions, Cardiovascular Thrombotic </paragraph>
                        <paragraph styleCode="Default">Events (5.1)                                                                 <content>       5/2016</content>
                        </paragraph>
                        <paragraph styleCode="Default">Warnings and Precautions, Heart Failure and Edema (5.5) <content>       5/2016</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="55c8ff2c-b266-4e30-a0f4-23b202013a68"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="Indications &amp; Usage Section"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20171225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph styleCode="Default">Meloxicam tablets are  a non-steroidal anti-inflammatory drug indicated for:</paragraph>
                        <list listType="unordered">
                           <item>Osteoarthritis (OA) (1.1)</item>
                           <item>Rheumatoid Arthritis (RA) (1.2)</item>
                           <item>Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="7fb9550c-ce5d-4c06-97ea-aa11dc79bb2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.1 Osteoarthritis (OA)</title>
                     <text>
                        <br/>
                        <paragraph>Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [<content styleCode="italics">see <linkHtml href="#Section_14.1">Clinical Studies (14.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="940b828f-fdd7-4b27-bb72-af22ad577265"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.2 Rheumatoid Arthritis (RA)</title>
                     <text>
                        <br/>
                        <paragraph>Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [<content styleCode="italics">see <linkHtml href="#Section_14.1">Clinical Studies (14.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.3">
                     <id root="061465a5-a603-4a96-9e2f-fe657e1430fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course</title>
                     <text>
                        <paragraph styleCode="Default">Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥60 kg [<content styleCode="italics">see Dosage and Administration (2.4) and Clinical Studies (14.2)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="b8844a6f-077a-4c16-a9a9-97343c4aa6e5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="Dosage &amp; Administration Section"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20171225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph styleCode="Default First">Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals <linkHtml href="#Section_2.1">(2.1)</linkHtml>
                        </paragraph>
                        <list listType="unordered">
                           <item>OA (2.2) and RA (2.3):</item>
                           <item>Starting dose: 7.5 mg once daily</item>
                           <item>Dose may be increased to 15 mg once daily</item>
                           <item>JRA (2.4):</item>
                           <item>7.5 mg once daily in children ≥60 kg</item>
                           <item>Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same (2.6)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="68730f76-e459-4f8d-873d-b78cf67e6d44"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 General Instructions</title>
                     <text>
                        <paragraph styleCode="Default">Carefully consider the potential benefits and risks of Meloxicam tablets and other treatment options before deciding to use Meloxicam tablets. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">After observing the response to initial therapy with Meloxicam tablets, adjust the dose to suit an individual patient's needs.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">In adults, the maximum recommended daily oral dose of Meloxicam tablets is 15 mg regardless of formulation. In patients with hemodialysis, a maximum daily dosage of 7.5 mg is recommended [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">Meloxicam tablets may be taken without regard to timing of meals.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="4237df22-73ba-4c76-9f14-81a6d9524a17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2 Osteoarthritis</title>
                     <text>
                        <paragraph>For the relief of the signs and symptoms of osteoarthritis the recommended starting and maintenance oral dose of Meloxicam tablets is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. </paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="9d33c373-5c25-4b30-b06f-c325b21857a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>For the relief of the signs and symptoms of rheumatoid arthritis, the recommended starting and maintenance oral dose of Meloxicam tablets is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. </paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="006bce66-820e-48d8-8d72-9beea8e49308"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course</title>
                     <text>
                        <paragraph styleCode="Default">For the treatment of juvenile rheumatoid arthritis, the recommended oral dose of Meloxicam tablets is 7.5 mg once daily in children who weigh ≥60 kg. There was no additional benefit demonstrated by increasing the dose above 7.5 mg in clinical trials.</paragraph>
                        <paragraph styleCode="Default">
                           <content>Meloxicam tablets should not be used in children who weigh &lt;60 kg.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="L2bb5ce37-8f47-4ec0-aeff-069fba11993c">
                     <id root="544d83fe-6eed-4060-9a06-7e5c3cd04a7d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Renal Impairment</title>
                     <text>
                        <paragraph styleCode="CM33">The use of Meloxicam tablets in subjects with severe renal impairment is not recommended.</paragraph>
                        <paragraph styleCode="CM33"/>
                        <paragraph styleCode="CM33">In patients on hemodialysis, the maximum dosage of Meloxicam tablets is 7.5 mg per day [<content styleCode="italics">see Clinical Pharmacology (12.3)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171226"/>
                  </section>
               </component>
               <component>
                  <section ID="L1e10d2d2-6136-4f0b-b8b0-c53da7d8231f">
                     <id root="56854cdc-5e6f-4822-83bc-2f313af44592"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Non-Interchangeability with Other Formulations of Meloxicam</title>
                     <text>
                        <paragraph styleCode="Default">Meloxicam tablets have not shown equivalent systemic exposure to other approved formulations of oral meloxicam. Therefore, Meloxicam tablets are not interchangeable with other formulations of oral meloxicam product even if the total milligram strength is the same. Do not substitute similar dose strengths of Meloxicam tablets with other formulations of oral meloxicam product.</paragraph>
                     </text>
                     <effectiveTime value="20171226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="3ef70d98-1386-4277-b21a-4b6ff8a76a8c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="Dosage Forms &amp; Strengths Section"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>
			   Tablets: </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        7.5 mg: Light yellow, round flat beveled edge tablet with “T“ on one side and “152” on the other side.</item>
                     <item>
                       15 mg: Light yellow, capsule shaped biconvex tablet with “T” on one side and “153” on the other side. </item>
                  </list>
               </text>
               <effectiveTime value="20171225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Tablets:  7.5 mg, 15 mg <linkHtml href="#Section_3">(3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="da3812cb-ce51-4c3b-8401-0c4dfa874d0e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="Contraindications Section"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20171225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Known hypersensitivity to meloxicam or any components of the drug product (4)</item>
                           <item>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4)</item>
                           <item>In the setting of CABG surgery (4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Le0cafbf9-345e-4f63-90f0-53cc60e00c4b">
                     <id root="ee722c1a-20c8-4517-b192-461941d24b9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph styleCode="CM33">Meloxicam tablets are contraindicated in the following patients:<content styleCode="bold"/>
                        </paragraph>
                        <list listType="unordered">
                           <item>Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [<content styleCode="italics">see Warnings and Precautions (5.7, 5.9)</content>]</item>
                           <item>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [<content styleCode="italics">see Warnings and Precautions (5.7, 5.8)</content>]</item>
                           <item>In the setting of coronary artery bypass graft (CABG) surgery [<content styleCode="italics">see Warnings and Precautions (5.1)</content>] <content styleCode="bold"/>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="c39ed15b-6a6c-4664-9ee3-4fdee335e20b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="Warnings And Precautions Section"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20171226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop (5.3)</item>
                           <item>
                              <content styleCode="underline">Hypertension</content>: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure (5.4, 7)</item>
                           <item>
                              <content styleCode="underline">Heart Failure and Edema</content>: Avoid use of Meloxicam in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (5.5)</item>
                           <item>
                              <content styleCode="underline">Renal Toxicity</content>: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of <content styleCode="underline">Meloxicam</content> in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (5.6)</item>
                           <item>
                              <content styleCode="underline">Anaphylactic Reactions</content>: Seek emergency help if an anaphylactic reaction occurs (5.7)</item>
                           <item>
                              <content styleCode="underline">Exacerbation of Asthma Related to Aspirin Sensitivity</content>: Meloxicam is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)</item>
                           <item>
                              <content styleCode="underline">Serious Skin Reactions</content>: Discontinue Meloxicam at first appearance of skin rash or other signs of hypersensitivity (5.9)</item>
                           <item>
                              <content styleCode="underline">Premature Closure of Fetal Ductus Arteriosus</content>: Avoid use in pregnant women starting at 30 weeks gestation (5.10, 8.1)</item>
                           <item>
                              <content styleCode="underline">Hematologic Toxicity</content>: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia (5.11, 7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="fd9f80be-9b92-436d-9f63-7a0df3787faa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Cardiovascular Thrombotic Events</title>
                     <text>
                        <paragraph styleCode="Default">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as meloxicam, increases the risk of serious gastrointestinal (GI) events [<content styleCode="italics">see Warnings and Precautions (5.2)</content>].</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="CM33">
                           <content styleCode="underline">Status Post Coronary Artery Bypass Graft (CABG) Surgery</content>
                        </paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="CM33">Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [<content styleCode="italics">see Contraindications (4)</content>].</paragraph>
                        <paragraph styleCode="CM33"/>
                        <paragraph styleCode="CM33">
                           <content styleCode="underline">Post-MI Patients </content>
                        </paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="CM33">Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.</paragraph>
                        <paragraph styleCode="CM33"/>
                        <paragraph styleCode="Default">Avoid the use of Meloxicam in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If Meloxicam is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="d688606f-44a2-4e34-a361-0220cc66474b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Gastrointestinal Bleeding, Ulceration, and Perforation</title>
                     <text>
                        <paragraph styleCode="Default First">NSAIDs, including meloxicam, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">
                           <content styleCode="underline">Risk Factors for GI Bleeding, Ulceration, and Perforation</content>
                        </paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">
                           <content styleCode="underline">Strategies to Minimize the GI Risks in NSAID-treated patients:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Use the lowest effective dosage for the shortest possible duration.</item>
                           <item>Avoid administration of more than one NSAID at a time.</item>
                           <item>Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs.</item>
                           <item>Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.</item>
                           <item>If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue Meloxicam until a serious GI adverse event is ruled out.</item>
                           <item>In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding [<content styleCode="italics">see Drug </content>
                              <content styleCode="italics">Interactions (7)</content>
                              <content>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20171226"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="398b548f-b4fc-48cf-9210-298c3db2491f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Hepatotoxicity</title>
                     <text>
                        <paragraph>Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported.</paragraph>
                        <paragraph/>
                        <paragraph>Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs including meloxicam.</paragraph>
                        <paragraph/>
                        <paragraph styleCode="Default">Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue Meloxicam immediately, and perform a clinical evaluation of the patient [<content styleCode="italics">see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="6cd1fc46-6770-41bd-8aab-7e67106fd4e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Hypertension</title>
                     <text>
                        <paragraph>NSAIDs, including Meloxicam, can lead to new onset or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                        <paragraph/>
                        <paragraph styleCode="Default">Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="56a894f3-5d6a-4440-9ecd-589c04193f30"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Heart Failure and Edema</title>
                     <text>
                        <paragraph>The Coxib and traditional NSAID Trialists’ Collaboration meta analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.</paragraph>
                        <paragraph/>
                        <paragraph>Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of meloxicam may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [<content styleCode="italics">see</content>
                           <content styleCode="italics"> Drug Interactions (7)</content>].</paragraph>
                        <paragraph/>
                        <paragraph styleCode="Default">Avoid the use of Meloxicam in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If Meloxicam is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="9af43f0e-787c-43bd-9b13-5712c886f2d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.6 Renal Toxicity and Hyperkalemia</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Renal Toxicity</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Long-term administration of NSAIDs, including Meloxicam, has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury.</paragraph>
                        <paragraph/>
                        <paragraph>Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</paragraph>
                        <paragraph/>
                        <paragraph>The renal effects of Meloxicam may hasten the progression of renal dysfunction in patients with preexisting renal disease. Because some Meloxicam metabolites are excreted by the kidney, monitor patients for signs of worsening renal function.</paragraph>
                        <paragraph/>
                        <paragraph styleCode="Default">Correct volume status in dehydrated or hypovolemic patients prior to initiating Meloxicam. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of Meloxicam [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">No information is available from controlled clinical studies regarding the use of Meloxicam in patients with advanced renal disease. Avoid the use of Meloxicam in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If Meloxicam is used in patients with advanced renal disease, monitor patients for signs of worsening renal function [<content styleCode="italics">see Clinical Pharmacology (12.3)</content>].</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph>
                           <content styleCode="underline">Hyperkalemia</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.</paragraph>
                     </text>
                     <effectiveTime value="20171226"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="0738a225-e952-471e-8086-a0714f880710"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.7 Anaphylactic Reactions</title>
                     <text>
                        <paragraph>Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma [<content styleCode="italics">see Contraindications (4) and Warnings and Precautions (5.8)</content>].</paragraph>
                        <paragraph/>
                        <paragraph styleCode="Default">Seek emergency help if an anaphylactic reaction occurs.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="12898918-b106-4895-ad43-fc73b148a324"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.8 Exacerbation of Asthma Related to Aspirin Sensitivity</title>
                     <text>
                        <paragraph>A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, Meloxicam is contraindicated in patients with this form of aspirin sensitivity [<content styleCode="italics">see Contraindications (4)</content>]. When Meloxicam is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="f8d53630-7e6d-4c26-9d66-2f4a80d239ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.9 Serious Skin Reactions</title>
                     <text>
                        <paragraph>NSAIDs, including meloxicam, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of Meloxicam at the first appearance of skin rash or any other sign of hypersensitivity. Meloxicam is contraindicated in patients with previous serious skin reactions to NSAIDs [<content styleCode="italics">see Contraindications (4)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="279a365f-a503-4542-b3ab-67a99fae972d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.10 Premature Closure of Fetal Ductus Arteriosus</title>
                     <text>
                        <paragraph styleCode="Default">Meloxicam may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including Meloxicam, in pregnant women starting at 30 weeks of gestation (third trimester) [<content styleCode="italics">see Use in Specific Populations (8.1)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.11">
                     <id root="e4aa1909-bf3a-44ae-bcfc-317396fa6b4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.11 Hematologic Toxicity</title>
                     <text>
                        <paragraph>Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with Meloxicam has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.</paragraph>
                        <paragraph/>
                        <paragraph>NSAIDs, including Meloxicam, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.12">
                     <id root="8e5fa525-436d-4fbd-87c3-9ec8dda4f1e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.12 Masking of Inflammation and Fever</title>
                     <text>
                        <paragraph>The pharmacological activity of Meloxicam in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.13">
                     <id root="cbb38d13-daa0-4ac5-8fdc-eee112af0b7c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.13 Laboratory Monitoring</title>
                     <text>
                        <paragraph styleCode="Default">Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [<content styleCode="italics">see Warnings and Precautions (5.2, 5.3, 5.6)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="ba4f6bb1-1fd3-44db-a68a-3753d8ea737e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="Adverse Reactions Section"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph styleCode="Default">The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Cardiovascular Thrombotic Events [<content styleCode="italics">see Boxed Warning and Warnings and Precautions (5.1)</content>]</item>
                     <item>GI Bleeding, Ulceration, and Perforation [<content styleCode="italics">see Boxed Warning and Warnings and Precautions (5.2)</content>]</item>
                     <item>Hepatotoxicity [<content styleCode="italics">see Warnings and Precautions (5.3)</content>]</item>
                     <item>Hypertension [<content styleCode="italics">see Warnings and Precautions (5.4)</content>]</item>
                     <item>Heart Failure and Edema [<content styleCode="italics">see Warnings and Precautions (5.5)</content>]</item>
                     <item>Renal Toxicity and Hyperkalemia [<content styleCode="italics">see Warnings and Precautions (5.6)</content>]</item>
                     <item>Anaphylactic Reactions [<content styleCode="italics">see Warnings and Precautions (5.7)</content>]</item>
                     <item>Serious Skin Reactions [<content styleCode="italics">see Warnings and Precautions (5.9)</content>]</item>
                     <item>Hematologic Toxicity [<content styleCode="italics">see Warnings and Precautions (5.11)</content>] </item>
                  </list>
               </text>
               <effectiveTime value="20171226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Most common (≥5% and greater than placebo) adverse events in adults are diarrhea, upper respiratory tract infections, dyspepsia, and influenza-like symptoms (6.1)</item>
                           <item>Adverse events observed in pediatric studies were similar in nature to the adult clinical trial experience (6.1)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Exelan Pharmaceuticals, Inc. at 1-855-295-7455 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="e889efaa-c5d5-455f-91cc-7846a7fb3b8b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph styleCode="Default First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph>
                           <content styleCode="italics">Adults </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Osteoarthritis and Rheumatoid Arthritis</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>The Meloxicam Phase 2/3 clinical trial database includes 10,122 OA patients and 1012 RA patients treated with Meloxicam 7.5 mg/day, 3505 OA patients and 1351 RA patients treated with Meloxicam 15 mg/day. Meloxicam at these doses was administered to 661 patients for at least 6 months and to 312 patients for at least one year. Approximately 10,500 of these patients were treated in ten placebo- and/or active-controlled osteoarthritis trials and 2363 of these patients were treated in ten placebo- and/or active-controlled rheumatoid arthritis trials. Gastrointestinal (GI) adverse events were the most frequently reported adverse events in all treatment groups across Meloxicam trials.</paragraph>
                        <paragraph/>
                        <paragraph>A 12-week multicenter, double-blind, randomized trial was conducted in patients with osteoarthritis of the knee or hip to compare the efficacy and safety of Meloxicam with placebo and with an active control. Two 12-week multicenter, double-blind, randomized trials were conducted in patients with rheumatoid arthritis to compare the efficacy and safety of Meloxicam with placebo.</paragraph>
                        <paragraph/>
                        <paragraph>Table 1a depicts adverse events that occurred in ≥2% of the Meloxicam treatment groups in a 12-week placebo- and active-controlled osteoarthritis trial.</paragraph>
                        <paragraph/>
                        <paragraph>Table 1b depicts adverse events that occurred in ≥2% of the Meloxicam treatment groups in two 12-week placebo-controlled rheumatoid arthritis trials.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="Lf9a9f0ae-9476-4360-9be8-be01366d892d"/>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Higher doses of Meloxicam (22.5 mg and greater) have been associated with an increased risk of serious GI events; therefore, the daily dose of Meloxicam should not exceed 15 mg.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Pediatrics </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Pauciarticular and Polyarticular Course Juvenile Rheumatoid Arthritis (JRA)</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Three hundred and eighty-seven patients with pauciarticular and polyarticular course JRA were exposed to Meloxicam with doses ranging from 0.125 to 0.375 mg/kg per day in three clinical trials. These studies consisted of two 12-week multicenter, double-blind, randomized trials (one with a 12-week open-label extension and one with a 40-week extension) and one 1-year open-label PK study. The adverse events observed in these pediatric studies with Meloxicam were similar in nature to the adult clinical trial experience, although there were differences in frequency. In particular, the following most common adverse events, abdominal pain, vomiting, diarrhea, headache, and pyrexia, were more common in the pediatric than in the adult trials. Rash was reported in seven (&lt;2%) patients receiving Meloxicam. No unexpected adverse events were identified during the course of the trials. The adverse events did not demonstrate an age or gender-specific subgroup effect.</paragraph>
                        <paragraph/>
                        <paragraph>The following is a list of adverse drug reactions occurring in &lt;2% of patients receiving Meloxicam in clinical trials involving approximately 16,200 patients.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="Lca69a704-2901-4649-aa09-1adca153c9b0"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20171226"/>
                     <component>
                        <observationMedia ID="Lf9a9f0ae-9476-4360-9be8-be01366d892d">
                           <text>tab1ab</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="tab1ab.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Lca69a704-2901-4649-aa09-1adca153c9b0">
                           <text>tab2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="tab2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="721e44e9-84c9-4af6-a133-5d4b44827e69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.2 Post Marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of Meloxicam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions about whether to include an adverse event from spontaneous reports in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) number of reports, or (3) strength of causal relationship to the drug. Adverse reactions reported in worldwide post marketing experience or the literature include: acute urinary retention; agranulocytosis; alterations in mood (such as mood elevation); anaphylactoid reactions including shock; erythema multiforme; exfoliative dermatitis; interstitial nephritis; jaundice; liver failure; Stevens-Johnson syndrome; toxic epidermal necrolysis, and infertility female.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="5f3a8238-5bb0-49b5-9547-ab5e65062dd7"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="Drug Interactions Section"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>See Table 3 for clinically significant drug interactions with meloxicam. See also <content styleCode="italics">Warnings and Precautions (5.2, 5.6, 5.11) and Clinical Pharmacology (12.3)</content>.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L8138d433-b169-4101-a11f-3f7e34d17a97"/>
                  </paragraph>
               </text>
               <effectiveTime value="20171226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs)</content>: Monitor patients for bleeding who are concomitantly taking Meloxicam with drugs that interfere with hemostasis. Concomitant use of Meloxicam and analgesic doses of aspirin is not generally recommended (7)<content styleCode="bold"/>
                           </item>
                           <item>
                              <content styleCode="underline">ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers</content>: Concomitant use with Meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure (7)<content styleCode="bold"/>
                           </item>
                           <item>
                              <content styleCode="underline">ACE Inhibitors and ARBs</content>: Concomitant use with Meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function (7)<content styleCode="bold"/>
                           </item>
                           <item>
                              <content styleCode="underline">Diuretics</content>: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects (7)<content styleCode="bold"/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="L8138d433-b169-4101-a11f-3f7e34d17a97">
                     <text>tab3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tab3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="6dfabd83-7d17-40d6-9549-09a5d5e5b889"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="Use In Specific Populations Section"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20171225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Pregnancy</content>: Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation (5.10, 8.1)</item>
                           <item>
                              <content styleCode="underline">Infertility</content>: NSAIDs are associated with reversible infertility. Consider withdrawal of Meloxicam in women who have difficulties conceiving (8.3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="40fac889-fecd-4483-aaed-8f0672937ed9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph styleCode="CM33">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="CM33">Use of NSAIDs, including Meloxicam, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including Meloxicam, in pregnant women starting at 30 weeks of gestation (third trimester) [<content styleCode="italics">see Warnings and Precautions (5.10)</content>].</paragraph>
                        <paragraph styleCode="CM33"/>
                        <paragraph>There are no adequate and well-controlled studies of Meloxicam in pregnant women. Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In the general U.S. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2-4% for major malformations, and 15-20% for pregnancy loss.</paragraph>
                        <paragraph/>
                        <paragraph>In animal reproduction studies, embryofetal death was observed in rats and rabbits treated during the period of organogenesis with meloxicam at oral doses equivalent to 0.65- and 6.5-times the maximum recommended human dose (MRHD) of Meloxicam. Increased incidence of septal heart defects were observed in rabbits treated throughout embryogenesis with meloxicam at an oral dose equivalent to 78-times the MRHD. In pre- and post-natal reproduction studies, there was an increased incidence of dystocia, delayed parturition, and decreased offspring survival at 0.08-times MRHD of meloxicam. No teratogenic effects were observed in rats and rabbits treated with meloxicam during organogenesis at an oral dose equivalent to 2.6 and 26-times the MRHD <content styleCode="italics">[see Data]</content>.</paragraph>
                        <paragraph/>
                        <paragraph>Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors, such as meloxicam, resulted in increased pre- and post-implantation loss.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Labor or Delivery </content>
                        </paragraph>
                        <paragraph>There are no studies on the effects of Meloxicam during labor or delivery. In animal studies, NSAIDs, including meloxicam, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>Meloxicam was not teratogenic when administered to pregnant rats during fetal organogenesis at oral doses up to 4 mg/kg/day (2.6-fold greater than the MRHD of 15 mg of Meloxicam based on BSA comparison). Administration of meloxicam to pregnant rabbits throughout embryogenesis produced an increased incidence of septal defects of the heart at an oral dose of 60 mg/kg/day (78-fold greater than the MRHD based on BSA comparison). The no effect level was 20 mg/kg/day (26-fold greater than the MRHD based on BSA conversion). In rats and rabbits, embryolethality occurred at oral meloxicam doses of 1 mg/kg/day and 5 mg/kg/day, respectively (0.65and 6.5-fold greater, respectively, than the MRHD based on BSA comparison) when administered throughout organogenesis.</paragraph>
                        <paragraph/>
                        <paragraph>Oral administration of meloxicam to pregnant rats during late gestation through lactation increased the incidence of dystocia, delayed parturition, and decreased offspring survival at meloxicam doses of 0.125 mg/kg/day or greater (0.08-times MRHD based on BSA comparison).</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="2832b2d1-6ecf-4e14-8974-77e25f91b9b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no human data available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Meloxicam and any potential adverse effects on the breastfed infant from the Meloxicam or from the underlying maternal condition.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>Meloxicam was present in the milk of lactating rats at concentrations higher than those in plasma.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="eb35bee7-279f-4975-b698-16626236f651"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Females </content>
                        </paragraph>
                        <paragraph>Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including Meloxicam, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including Meloxicam, in women who have difficulties conceiving or who are undergoing investigation of infertility.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="c086c071-454f-4bc4-baa2-b61a0144d820"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of meloxicam in pediatric JRA patients from 2 to 17 years of age has been evaluated in three clinical trials [<content styleCode="italics">see Dosage and Administration (2.3), Adverse Reactions (6.1) and Clinical Studies (14.2)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="b315e292-59be-4bbc-86a7-caf93fb1d636"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [<content styleCode="italics">see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 5.13)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="5bbfec72-4894-423a-a52f-b3e8d7cd8546"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment have not been adequately studied. Since meloxicam is significantly metabolized in the liver and hepatotoxicity may occur, use meloxicam with caution in patients with hepatic impairment [<content styleCode="italics">see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="b086da95-01f9-4c74-bf96-eb49aa714c70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been studied. The use of Meloxicam in subjects with severe renal impairment is not recommended. In patients on hemodialysis, meloxicam should not exceed 7.5 mg per day. Meloxicam is not dialyzable [<content styleCode="italics">see Dosage and Administration (2.1) and Clinical Pharmacology (12.3)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="6f7ed43c-656f-4e94-955e-0e3ac2444f70"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="Overdosage Section"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph styleCode="CM33">Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [<content styleCode="italics">see Warnings and Precautions (5.1, 5.2, 5.4, 5.6)</content>].</paragraph>
                  <paragraph styleCode="CM33"/>
                  <paragraph styleCode="CM33">Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</paragraph>
                  <paragraph styleCode="CM33"/>
                  <paragraph>There is limited experience with meloxicam overdosage. Cholestyramine is known to accelerate the clearance of meloxicam. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdosage.</paragraph>
                  <paragraph/>
                  <paragraph>For additional information about overdosage treatment, call a poison control center (1-800-222-1222).</paragraph>
               </text>
               <effectiveTime value="20171225"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="7bcd9b08-dbc5-4b7c-896f-d93d408de193"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="Description Section"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <br/>
                  <paragraph>Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as 4-hydroxy-2-methyl-<content styleCode="italics">N</content>-(5-methyl-2-thiazolyl)-2<content styleCode="italics">H</content>-1,2-benzothiazine-3-­carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> and it has the following structural formula:</paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM3"/>
                  <br/>
                  <paragraph>Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)<sub>app</sub> = 0.1 in <content styleCode="italics">n</content>-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2.<br/>
                     <br/>Meloxicam is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam.<br/>
                     <br/>The inactive ingredients in Meloxicam tablets USP include colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium citrate dihydrate.</paragraph>
               </text>
               <effectiveTime value="20171225"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="MM3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="554b9de6-e1a1-4420-90fe-6802cfd5a16c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="Clinical Pharmacology Section"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20171226"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="5c8cbfd6-a791-4348-bf30-b3ba536efd90"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Meloxicam has analgesic, anti-inflammatory, and antipyretic properties.</paragraph>
                        <paragraph/>
                        <paragraph styleCode="CM33">The mechanism of action of Meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph>Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="d4a616f4-fc31-413d-a509-a7aea689a70e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                           <br/>
                           <br/>The absolute bioavailability of meloxicam capsules was 89% following a single oral dose of 30 mg compared with 30 mg IV bolus injection. Following single intravenous doses, dose-proportional pharmacokinetics were shown in the range of 5 mg to 60 mg. After multiple oral doses the pharmacokinetics of meloxicam capsules were dose-proportional over the range of 7.5 mg to 15 mg. Mean C<sub>max</sub> was achieved within four to five hours after a 7.5 mg meloxicam tablet was taken under fasted conditions, indicating a prolonged drug absorption. With multiple dosing, steady-state concentrations were reached by Day 5. A second meloxicam concentration peak occurs around 12 to 14 hours post-dose suggesting biliary recycling.<br/>
                           <br/>Meloxicam capsules have been shown to be bioequivalent to Meloxicam tablets.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="L8086ecb3-51cd-4a40-994f-2677f9965814"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Food and Antacid Effects</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>Administration of meloxicam capsules following a high fat breakfast (75 g of fat) resulted in mean peak drug levels (i.e., Cmax) being increased by approximately 22% while the extent of absorption (AUC) was unchanged. The time to maximum concentration (Tmax) was achieved between 5 and 6 hours. No pharmacokinetic interaction was detected with concomitant administration of antacids. Based on these results, Meloxicam can be administered without regard to timing of meals or concomitant administration of antacids.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The mean volume of distribution (Vss) of meloxicam is approximately 10 L. Meloxicam is ~99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to ~99% in patients with renal disease. Meloxicam penetration into human red blood cells, after oral dosing, is less than 10%. Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam.</paragraph>
                        <paragraph/>
                        <paragraph>Meloxicam concentrations in synovial fluid, after a single oral dose, range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid as compared to plasma. The significance of this penetration is unknown.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Elimination </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Metabolism </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Meloxicam is extensively metabolized in the liver. Meloxicam metabolites include 5'-carboxy meloxicam (60% of dose), from P-450 mediated metabolism formed by oxidation of an intermediate metabolite 5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of dose). <content styleCode="italics">In vitro </content>studies indicate that CYP2C9 (cytochrome P450 metabolizing enzyme) plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. Patients’ peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose, respectively. All the four metabolites are not known to have any <content styleCode="italics">in vivo </content>pharmacological activity.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6%, and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively. There is significant biliary and/or enteral secretion of the drug. This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50%.</paragraph>
                        <paragraph/>
                        <paragraph>The mean elimination half-life (t1/2) ranges from 15 hours to 20 hours. The elimination half-life is constant across dose levels indicating linear metabolism within the therapeutic dose range. Plasma clearance ranges from 7 to 9 mL/min.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>After single (0.25 mg/kg) dose administration and after achieving steady state (0.375 mg/kg/day), there was a general trend of approximately 30% lower exposure in younger patients (2 to 6 years old) as compared to the older patients (7 to 16 years old). The older patients had meloxicam exposures similar (single dose) or slightly reduced (steady state) to those in the adult patients, when using AUC values normalized to a dose of 0.25 mg/kg [<content styleCode="italics">see Dosage and Administration (2.4)</content>]. The meloxicam mean (SD) elimination half-life was 15.2 (10.1) and 13.0 hours (3.0) for the 2 to 6 year old patients, and 7 to 16 year old patients, respectively.</paragraph>
                        <paragraph/>
                        <paragraph>In a covariate analysis, utilizing population pharmacokinetics body-weight, but not age, was the single predictive covariate for differences in the meloxicam apparent oral plasma clearance. The body-weight normalized apparent oral clearance values were adequate predictors of meloxicam exposure in pediatric patients.</paragraph>
                        <paragraph/>
                        <paragraph>The pharmacokinetics of Meloxicam in pediatric patients under 2 years of age have not been investigated.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Geriatric</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>Elderly males (≥65 years of age) exhibited meloxicam plasma concentrations and steady-state pharmacokinetics similar to young males. Elderly females (≥65 years of age) had a 47% higher AUCss and 32% higher Cmax,ss as compared to younger females (≤55 years of age) after body weight normalization. Despite the increased total concentrations in the elderly females, the adverse event profile was comparable for both elderly patient populations. A smaller free fraction was found in elderly female patients in comparison to elderly male patients.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Sex </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Young females exhibited slightly lower plasma concentrations relative to young males. After single doses of 7.5 mg Meloxicam, the mean elimination half-life was 19.5 hours for the female group as compared to 23.4 hours for the male group. At steady state, the data were similar (17.9 hours vs 21.4 hours). This pharmacokinetic difference due to gender is likely to be of little clinical importance. There was linearity of pharmacokinetics and no appreciable difference in the Cmax or Tmax across genders.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Following a single 15 mg dose of meloxicam there was no marked difference in plasma concentrations in patients with mild (Child-Pugh Class I) or moderate (Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein binding of meloxicam was not affected by hepatic impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied [<content styleCode="italics">see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)</content>].</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>Meloxicam pharmacokinetics have been investigated in subjects with mild and moderate renal impairment. Total drug plasma concentrations of meloxicam decreased and total clearance of meloxicam increased with the degree of renal impairment while free AUC values were similar in all groups. The higher meloxicam clearance in subjects with renal impairment may be due to increased fraction of unbound meloxicam which is available for hepatic metabolism and subsequent excretion. No dosage adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been adequately studied. The use of Meloxicam in subjects with severe renal impairment is not recommended [<content styleCode="italics">see Dosage and Administration (2.5), Warnings and Precautions (5.6) and Use in Specific Populations (8.7)</content>].</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Hemodialysis </content>
                        </paragraph>
                        <paragraph>Following a single dose of meloxicam, the free Cmax plasma concentrations were higher in patients with renal failure on chronic hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialyzable [<content styleCode="italics">see Dosage and Administration (2.1) and Use in Specific Populations (8.7)</content>].</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph styleCode="CM33">
                           <content styleCode="italics">Aspirin: </content>When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. When Meloxicam is administered with aspirin (1000 mg three times daily) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known. See Table 3 for clinically significant drug interactions of NSAIDs with aspirin [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="Default">
                           <content styleCode="italics">Cholestyramine: </content>Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. This resulted in a decrease in t<sub>1/2</sub>, from 19.2 hours to 12.5 hours, and a 35% reduction in AUC. This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. The clinical relevance of this interaction has not been established.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph>
                           <content styleCode="italics">Cimetidine: </content>Concomitant administration of 200 mg cimetidine four times daily did not alter the single-dose pharmacokinetics of 30 mg meloxicam.</paragraph>
                        <paragraph/>
                        <paragraph styleCode="CM33">
                           <content styleCode="italics">Digoxin: </content>Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after β-acetyldigoxin administration for 7 days at clinical doses. <content styleCode="italics">In vitro </content>testing found no protein binding drug interaction between digoxin and meloxicam.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="CM33">
                           <content styleCode="italics">Lithium: </content>In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg twice daily with meloxicam 15 mg QD every day as compared to subjects receiving lithium alone [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                        <paragraph styleCode="CM33"/>
                        <paragraph styleCode="CM33">
                           <content styleCode="italics">Methotrexate: </content>A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. <content styleCode="italics">In vitro</content>, methotrexate did not displace meloxicam from its human serum binding sites [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph>
                           <content styleCode="italics">Warfarin: </content>The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. However, one subject showed an increase in INR from 1.5 to 2.1. Caution should be used when administering Meloxicam with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20171226"/>
                     <component>
                        <observationMedia ID="L8086ecb3-51cd-4a40-994f-2677f9965814">
                           <text>tab4</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="tab4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="e14f6690-6da3-400b-8954-6fa2eed9bce2"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="Nonclinical Toxicology Section"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20171225"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="6b16dd28-26ca-4377-b28a-6796a2b4660b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph styleCode="CM33">
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph styleCode="CM33">There was no increase in tumor incidence in long-term carcinogenicity studies in rats (104 weeks) and mice (99 weeks) administered meloxicam at oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg/day in mice (up to 0.5-and 2.6-times, respectively, the maximum recommended human dose [MRHD] of 15 mg/day Meloxicam based on body surface area [BSA] comparison).</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph styleCode="CM33">
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph styleCode="CM33">Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome aberration assay with human lymphocytes and an <content styleCode="italics">in vivo </content>micronucleus test in mouse bone marrow.</paragraph>
                        <paragraph styleCode="Default"/>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Meloxicam did not impair male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 mg/kg/day in females (up to 5.8- and 3.2-times greater, respectively, than the MRHD based on BSA comparison).</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="b32cf037-047d-4cc5-b7b0-5f544a79136c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="Clinical Studies Section"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20171225"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="a0b2f354-f5da-46e8-b2d6-9e00b812a641"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.1 Osteoarthritis and Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>The use of Meloxicam for the treatment of the signs and symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week, double-blind, controlled trial. Meloxicam (3.75 mg, 7.5 mg, and 15 mg daily) was compared to placebo. The four primary endpoints were investigator’s global assessment, patient global assessment, patient pain assessment, and total WOMAC score (a self-administered questionnaire addressing pain, function, and stiffness). Patients on Meloxicam 7.5 mg daily and Meloxicam 15 mg daily showed significant improvement in each of these endpoints compared with placebo.</paragraph>
                        <paragraph/>
                        <paragraph>The use of Meloxicam for the management of signs and symptoms of osteoarthritis was evaluated in six double-blind, active-controlled trials outside the U.S. ranging from 4 weeks’ to 6 months’ duration. In these trials, the efficacy of Meloxicam, in doses of 7.5 mg/day and 15 mg/day, was comparable to piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with the efficacy seen in the U.S. trial.</paragraph>
                        <paragraph/>
                        <paragraph>The use of Meloxicam for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in a 12-week, double-blind, controlled multinational trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was compared to placebo. The primary endpoint in this study was the ACR20 response rate, a composite measure of clinical, laboratory, and functional measures of RA response. Patients receiving Meloxicam 7.5 mg and 15 mg daily showed significant improvement in the primary endpoint compared with placebo. No incremental benefit was observed with the 22.5 mg dose compared to the 15 mg dose.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="e30dbcfd-929e-496f-a95e-e9c5f9ea5425"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.2 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course</title>
                     <text>
                        <paragraph>The use of Meloxicam for the treatment of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older was evaluated in two 12-week, double-blind, parallel-arm, active-controlled trials.</paragraph>
                        <paragraph/>
                        <paragraph>Both studies included three arms: naproxen and two doses of meloxicam. In both studies, meloxicam dosing began at 0.125 mg/kg/day (7.5 mg maximum) or 0.25 mg/kg/day (15 mg maximum), and naproxen dosing began at 10 mg/kg/day. One study used these doses throughout the 12-week dosing period, while the other incorporated a titration after 4 weeks to doses of 0.25 mg/kg/day and 0.375 mg/kg/day (22.5 mg maximum) of meloxicam and 15 mg/kg/day of naproxen.</paragraph>
                        <paragraph/>
                        <paragraph>The efficacy analysis used the ACR Pediatric 30 responder definition, a composite of parent and investigator assessments, counts of active joints and joints with limited range of motion, and erythrocyte sedimentation rate. The proportion of responders were similar in all three groups in both studies, and no difference was observed between the meloxicam dose groups.</paragraph>
                     </text>
                     <effectiveTime value="20171225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="33dc1656-ee9b-4c48-9faa-61532b1987e0"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="How Supplied Section"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Meloxicam Tablets USP are available as Light yellow, round flat beveled edge tablet with "T" on one side and "152" on the other side for 7.5 mg or as Light yellow, capsule shaped biconvex tablet with "T" on one side and "153" on the other side for 15 mg.</paragraph>
                  <paragraph/>
                  <paragraph>Meloxicam Tablets USP 7.5 mg are available as follows:</paragraph>
                  <paragraph>NDC 76282-152-30; Bottles of 30</paragraph>
                  <paragraph>NDC 76282-152-01; Bottles of 100</paragraph>
                  <paragraph>NDC 76282-152-05; Bottles of 500</paragraph>
                  <paragraph>NDC 76282-152-10; Bottles of 1000</paragraph>
                  <paragraph/>
                  <paragraph>Meloxicam Tablets USP 15 mg are available as follows:</paragraph>
                  <paragraph>NDC 76282-153-30; Bottles of 30</paragraph>
                  <paragraph>NDC 76282-153-01; Bottles of 100</paragraph>
                  <paragraph>NDC 76282-153-05; Bottles of 500</paragraph>
                  <paragraph>NDC 76282-153-10; Bottles of 1000</paragraph>
                  <paragraph/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Storage </content>
                     <content styleCode="bold">Store at 20<sup>0</sup> to 25<sup>0</sup>C (68<sup>0</sup> to 77<sup>0</sup>F) [See USP Controlled Room Temperature]. </content>Keep Meloxicam Tablets USP in a dry place</paragraph>
                  <paragraph styleCode="Default"/>
                  <paragraph styleCode="CM33">Dispense tablets in a tight container.</paragraph>
                  <paragraph styleCode="Default"/>
                  <paragraph>Keep this and all medications out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20171225"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="faab34ff-4754-4ac1-9b81-a4d35e0acff0"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="Information For Patients Section"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph styleCode="CM33 First">Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed.</paragraph>
                  <paragraph styleCode="Default"/>
                  <paragraph styleCode="CM33">Inform patients, families or their caregivers of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy.</paragraph>
                  <paragraph styleCode="CM33"/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Cardiovascular Thrombotic Events</content>
                  </paragraph>
                  <paragraph styleCode="CM33">Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their healthcare provider immediately [see Warnings and Precautions (5.1)].</paragraph>
                  <paragraph styleCode="Default"/>
                  <paragraph>
                     <content styleCode="underline">Gastrointestinal Bleeding, Ulceration, and Perforation</content>
                  </paragraph>
                  <paragraph>Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their healthcare provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for the signs and symptoms of GI bleeding [see Warnings and Precautions (5.2)].</paragraph>
                  <paragraph/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph styleCode="CM33">Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, instruct patients to stop Meloxicam tablets and seek immediate medical therapy [<content styleCode="italics">see Warnings and Precautions (5.3)</content>].</paragraph>
                  <paragraph styleCode="CM33"/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Heart Failure and Edema</content>
                  </paragraph>
                  <paragraph styleCode="CM33">Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [<content styleCode="italics">see Warnings and Precautions (5.5)</content>].</paragraph>
                  <paragraph styleCode="Default"/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Anaphylactic Reactions</content>
                  </paragraph>
                  <paragraph styleCode="CM33">Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [<content styleCode="italics">see Contraindications (4) and Warnings and Precautions (5.7)</content>].</paragraph>
                  <paragraph styleCode="CM33"/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Serious Skin Reactions</content>
                  </paragraph>
                  <paragraph styleCode="CM33">Advise patients to stop Meloxicam tablets immediately if they develop any type of rash and to contact their healthcare provider as soon as possible [<content styleCode="italics">see Warnings and Precautions (5.9)</content>].</paragraph>
                  <paragraph styleCode="Default"/>
                  <paragraph>
                     <content styleCode="underline">Female Fertility</content>
                  </paragraph>
                  <paragraph>Advise females of reproductive potential who desire pregnancy that NSAIDs, including Meloxicam tablets, may be associated with a reversible delay in ovulation [<content styleCode="italics">see Use in Specific Populations (8.3)</content>].</paragraph>
                  <paragraph/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Fetal Toxicity</content>
                  </paragraph>
                  <paragraph styleCode="CM33">Inform pregnant women to avoid use of Meloxicam tablets and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus [<content styleCode="italics">see Warnings and Precautions (5.10) and Use in Specific Populations (8.1)</content>].</paragraph>
                  <paragraph styleCode="CM33"/>
                  <paragraph styleCode="CM33">
                     <content styleCode="underline">Avoid Concomitant Use of NSAIDs</content>
                  </paragraph>
                  <paragraph styleCode="CM33">Inform patients that the concomitant use of Meloxicam tablets with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [<content styleCode="italics">see Warnings and Precautions (5.2) and Drug Interactions (7)</content>]. Alert patients that NSAIDs may be present in “over the counter” medications for treatment of colds, fever, or insomnia.</paragraph>
                  <paragraph styleCode="CM33"/>
                  <paragraph>
                     <content styleCode="underline">Use of NSAIDs and Low-Dose Aspirin</content>
                  </paragraph>
                  <paragraph>Inform patients not to use low-dose aspirin concomitantly with Meloxicam tablets until they talk to their healthcare provider [<content styleCode="italics">see Drug Interactions (7)</content>].</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Please address medical inquiries to 1-855-295-7455</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content>Manufactured by:</content>
                  </paragraph>
                  <paragraph>Ascent Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Central Islip, NY 11722</paragraph>
                  <paragraph/>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Exelan Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Lawrenceville, GA 30046</paragraph>
                  <paragraph/>
                  <paragraph>Rev: 12/17</paragraph>
               </text>
               <effectiveTime value="20171226"/>
            </section>
         </component>
         <component>
            <section ID="Section_19">
               <id root="b1889de1-dde5-4f4d-af71-622cbfa03de3"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <paragraph/>
                  <table>
                     <caption/>
                     <tbody>
                        <tr>
                           <td valign="top">
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph/>
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?</content>
                              </paragraph>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">NSAIDs can cause serious side effects, including: </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Increased risk of a heart attack or stroke that can lead to death</content>. This risk may happen early in treatment and may increase:</item>
                                 <item>with increasing doses of NSAIDs</item>
                                 <item>with longer use of NSAIDs</item>
                              </list>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">Do not take NSAIDs right before or after a heart surgery called a “coronary artery bypass graft (CABG).” </content>
                              </paragraph>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: </content>
                                 </item>
                              </list>     o  anytime during use<br/>     o  without warning symptoms<br/>     o  that may cause death<br/>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">The risk of getting an ulcer or bleeding increases with:</content>
                              </paragraph>
                              <paragraph styleCode="Default"/>
                              <paragraph>    o past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs</paragraph>
                              <paragraph>    o taking medicines called "corticosteroides". "anticoagulants", "SSRIs", or "SNRIs"</paragraph>
                              <paragraph>    o increasing doses of NSAIDs     oolder age</paragraph>
                              <paragraph>    o longer use of NSAIDs            opoor health</paragraph>
                              <paragraph>    o smoking                                o advanced liver disease</paragraph>
                              <paragraph>    o drinking alcohol                     o bleeding problems</paragraph>
                              <paragraph/>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">NSAIDs should only be used:</content>
                              </paragraph>    o exactly as prescribed<br/>    o at the lowest dose possible for your treatment<br/>    o for the shortest time needed<br/>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">What are NSAIDs? </content>
                              </paragraph>
                              <paragraph styleCode="Default">NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">Who should not take NSAIDs? </content>
                              </paragraph>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">Do not take NSAIDs: </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs.</item>
                                 <item>right before or after heart bypass surgery.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you: </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>have liver or kidney problems</item>
                                 <item>have high blood pressure</item>
                                 <item>have asthma</item>
                                 <item>are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking NSAIDs during pregnancy. <content styleCode="bold">You should not take NSAIDs after 29 weeks of pregnancy. </content>
                                 </item>
                                 <item>are breastfeeding or plan to breast feed.</item>
                              </list>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. </content>NSAIDs and some other medicines can interact with each other and cause serious side effects. <content styleCode="bold">Do not start taking any new medicine without talking to your healthcare provider first. </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph/>
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">What are the possible side effects of NSAIDs? </content>
                              </paragraph>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">NSAIDs can cause serious side effects, including: </content>
                              </paragraph>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">See “What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?”</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>new or worse high blood pressure</item>
                                 <item>heart failure</item>
                                 <item>liver problems including liver failure</item>
                                 <item>kidney problems including kidney failure</item>
                                 <item>low red blood cells (anemia)</item>
                                 <item>life-threatening skin reactions</item>
                                 <item>life-threatening allergic reactions</item>
                                 <item>
                                    <content styleCode="bold">Other side effects of NSAIDs include: </content>stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Get emergency help right away if you get any of the following symptoms:</content>
                              </paragraph>
                              <paragraph>• shortness of breath or trouble breathing           • slurred speech<br/>• chest pain                                                      • swelling of the face or throat<br/>• weakness in one part or side of your body</paragraph>
                              <paragraph/>
                              <paragraph styleCode="Default">
                                 <content styleCode="bold">Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms: </content>
                              </paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="bold">• nausea                                                     </content>  • vomit blood</paragraph>
                              <paragraph>• more tired or weaker than usual                   • there is blood in your bowel movement or it is black and sticky like tar<br/>• diarrhea                                                     • unusual weight gain<br/>• itching                                                       • skin rash or blisters with fever<br/>• your skin or eyes look yellow                       • swelling of the arms, legs, hands and feet<br/>• indigestion or stomach pain<br/>• flu-like symptoms</paragraph>
                              <paragraph>
                                 <content styleCode="bold">These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs.If you take too much of your NSAID, call your healthcare provider or get medical help right away.</content>
                              </paragraph>
                              <paragraph styleCode="Default"/>
                              <paragraph styleCode="Default">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">Other information about NSAIDs: </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.</item>
                                 <item>Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph styleCode="Default First">
                                 <content styleCode="bold">General information about the safe and effective use of NSAIDs </content>
                              </paragraph>
                              <paragraph styleCode="Default"/>
                              <paragraph styleCode="Default">Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                              <paragraph styleCode="Default"/>
                              <paragraph styleCode="Default">If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>Ascent Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Central Islip, NY 11722</paragraph>
                  <paragraph/>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Exelan Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Lawrenceville, GA 30046</paragraph>
                  <paragraph/>
                  <paragraph>Rev: 12/17</paragraph>
               </text>
               <effectiveTime value="20171228"/>
            </section>
         </component>
         <component>
            <section ID="Section_20">
               <id root="23a829db-94bb-4f63-a675-ae15c6c4a132"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">NDC 76282-152-10</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> Meloxicam Tablets USP 7.5 mg </content>
                  </paragraph>
                  <paragraph>Rx only          1000 Tablets</paragraph>
                  <paragraph>EXELAN PHARMACEUTICALS, INC.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">NDC 76282-153-10</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> Meloxicam Tablets USP 15 mg </content>
                  </paragraph>
                  <paragraph>Rx only          1000 Tablets</paragraph>
                  <paragraph>EXELAN PHARMACEUTICALS, INC.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20171226"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>7.5mg-100</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="MM1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>15mg-100</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="MM2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>